ArticleLife (Basel, Switzerland)2026
LDN-27219 Modulates High-Glucose-Induced Endothelial Bioenergetic Remodeling and MitoSOX Red Fluorescence.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundEndothelial dysfunction is a key feature of diabetic vascular disease and is associated with high-glucose-induced changes in endothelial energy metabolism and redox balance. Transglutaminase-2 has been implicated in vascular stress responses, but its contribution to endothelial adaptation to high glucose remains incompletely defined.
methodsEA.hy926 endothelial cells were cultured under normoglycaemic (NG) or high-glucose conditions and treated with LDN-27219 at 20 µg/mL (48.9 µM). Cellular reducing capacity, total protein content, mitochondrial respiration, MitoSOX Red fluorescence, and selected cytokine and adhesion-marker secretion were assessed.
resultsHigh glucose shifted cells toward a more glycolytic basal phenotype, increased MitoSOX Red fluorescence, and reduced glycolytic stress responsiveness compared with NG conditions. LDN-27219 had limited effects under NG conditions but, under high-glucose conditions, reduced basal respiration, maximal respiration, ATP-linked oxygen consumption, and spare respiratory capacity, while partially restoring stressed extracellular acidification. LDN-27219 also reduced high-glucose-induced MitoSOX Red fluorescence, although this cannot be interpreted as definitive evidence of reduced mitochondrial superoxide production because mitochondrial membrane potential was not measured. No statistically significant changes were detected in the selected inflammatory or adhesion markers.
conclusionsLDN-27219 modifies endothelial bioenergetic and oxidant-associated fluorescence responses under high-glucose conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.